Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Post-chemotherapy exercise significantly boosts disease-free survival in colon cancer patients, underscoring the importance ...

Worried that President Donald Trump’s FDA might not act, a panel of cancer experts recommended that doctors consider testing ...

A structured exercise program after surgery and adjuvant chemotherapy reduced the risk for cancer recurrence and death for ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...